二价口蹄疫mRNA疫苗诱导均衡的体液与细胞免疫应答
研究开发了靶向口蹄疫病毒A型和O型的二价mRNA@LNP疫苗,设计整合了VP1蛋白优化免疫优势表位与3A非结构蛋白保守T细胞表位。小鼠实验显示该疫苗比灭活疫苗诱导更快的早期免疫激活和更强的体液与细胞免疫应答,5 μg mRNA@LNP抗体水平始终与5 μg灭活疫苗相当,加强免疫后10 μg mRNA剂量免疫效果与ISA 206佐剂灭活疫苗一致。
要点
- 二价mRNA@LNP疫苗靶向FMDV A型和O型,整合VP1优化表位与3A保守T细胞表位。
- 5 μg mRNA@LNP抗体水平始终与5 μg灭活疫苗相当,10 μg加强后与ISA 206佐剂灭活疫苗一致。
- mRNA疫苗诱导Th1偏向免疫应答,细胞免疫强于ISA-206佐剂灭活疫苗。
核心结论
- 二价mRNA@LNP疫苗可诱导体液免疫与灭活疫苗相当、细胞免疫更均衡强健的应答,支持mRNA作为无病毒多价口蹄疫疫苗平台。
研究设计与样本
- 研究开发靶向FMDV A型和O型的二价mRNA@LNP疫苗,整合VP1蛋白优化免疫优势表位与3A非结构蛋白保守T细胞表位,体外验证抗原表达后在小鼠中评价免疫原性。
主要发现
- mRNA@LNP比灭活病毒疫苗诱导更快的早期免疫激活和更强的体液与细胞免疫应答。
- 整个免疫期间5 μg mRNA@LNP诱导的抗体水平始终与5 μg灭活疫苗相当。
- 加强免疫后10 μg mRNA剂量免疫效果与ISA 206佐剂灭活疫苗一致。
- 液体阻断ELISA显示mRNA@LNP诱导强阻断抗体滴度:A型5 μg时滴度>256,O型10 μg时滴度>128。
- 抗体同型分析显示高IgG2a/IgG1比值及高IFN-γ,提示Th1偏向免疫应答,与GC B细胞和CTL激活增强一致;ISA-206佐剂疫苗细胞免疫较弱且更Th2偏向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Foot-and-mouth disease (FMD) poses a significant threat to global livestock industries due to its high viral contagiousness. Despite inactivated viral vaccines remaining effective, their production requires stringent biocontainment and faces limitations in stability and cross-serotype immunogenicity. Here, we developed a novel bivalent mRNA@LNP vaccine targeting FMDV serotypes A and O. The design incorporated optimized immunodominant epitopes from the VP1 protein, combined with a conserved T-cell epitope from 3A non-structural protein. We validated antigen expression in vitro and evaluated the immunogenicity of mRNA@LNP in mice. It elicited faster early immune activation and stronger humoral and cellular immune responses than the inactivated virus vaccine. Throughout the entire immunization period, the antibody levels induced by 5 μg mRNA@LNP were consistently equivalent to those of the 5 μg inactivated vaccine. Furthermore, the immune efficacy of the 10 μg mRNA dose following the booster vaccination was consistent to that of the ISA 206-adjuvanted inactivated vaccine. Liquid-blocking ELISA indicated that immunization of the mRNA@LNP induced strong blocking antibody titers against both serotype A(titer>256 at 5 μg) and serotype O(titer>128 at 10 μg). Antibody isotyping (high IgG2a/IgG1 ratio) and cytokine profiling (high IFN-γ) revealed a pronounced Th1-skewed immune response, consistent with enhanced GC B cell activation and CTL activation. In contrast, the ISA-206 adjuvanted vaccine induced a weaker cellular immune response and a more Th2-biased profile, highlighting the capacity of the mRNA vaccine to achieve not only comparable humoral immunogenicity to inactivated vaccines but also a more balanced and robust cellular immunity. These findings support mRNA vaccines as a promising, virus-free platform for multivalent FMD vaccines, offering potential solutions to current limitations and providing broader protection against FMDV outbreaks.
引用
- Wang L, Li Z, Zhu H, et al. Bivalent foot-and-mouth disease virus mRNA vaccine induces well-balanced humoral and cellular immune responses. Vaccine. 2026. PMID: 42320384. doi:10.1016/j.vaccine.2026.128840
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。